Becton, Dickinson and Company (BD) is in a transformative period in its development. The medication delivery to lab tests and biosciences research company has been reinventing itself and its approach to the evolving medtech market in the past decade. The die was cast when the now 127-year-old company bought CareFusion Corporation in 2015 and then in 2017 followed it with another major transaction, the purchase of C.R. Bard.
BD Moves The Needle To High Growth Segments
Exploiting The Trend To Pharmacy Automation And Remote Patient Care
Becton Dickinson is investing in high-growth segments and is on a mission to simplify its business. CEO Tom Polen’s 2025 strategy targets 25% operating margin from both innovations and durable core business combined, as senior BD executives told In Vivo during a break at J.P. Morgan 2024.
